Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer

Cancer Letters

Volumn 278, Issue 1, 2009, Pages 56-64

  Zhang, Zhenbo ^a   Jia, Lin ^b   Feng, Youji ^a   Zheng, Wenxin ^c,d  

^a FUDAN UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

FSHR; Gonadotropin; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLLITROPIN; FOLLITROPIN RECEPTOR; MYC PROTEIN; PROHIBITIN;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DNA PRIMERS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTORS, FSH; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSFECTION;

EID: 63449142604     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.024     Document Type: Article

References (49)

1. Fathalla M.F. Incessant ovulation - a factor in ovarian neoplasia?. Lancet 2 (1971) 163
2. Casagrande J.T., et al. Lancet 2 (1979) 170-173
3. Biskind M.S., and Biskind G.S. Development of tumors in the rat ovary after transplantation into the spleen. Proc. Soc. Exp. Biol. Med. 55 (1944) 176-179
4. Cramer D.W., and Welch W.R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl. Cancer Inst. 71 (1983) 717-721
5. Risch H.A. Hormonal etiology of epithelial ovarian cancer with a hypothesis concerning the role of androgens and progesterone. J. Natl. Cancer Inst. 90 (1998) 1774-1786
6. Leung P.C., and Choi J.H. Endocrine signaling in ovarian surface epithelium and cancer. Hum. Reprod. Update 13 (2007) 143-162
7. Brekelmans C.T. Risk factors and risk reduction of breast and ovarian cancer. Curr. Opin. Obstet. Gynecol. 15 (2003) 63-68
8. Riman T., Persson I., and Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin. Endocrinol. (Oxf) 49 (1998) 695-707
9. Ohtani K., et al. Follicle-stimulating hormone promotes the growth of human epithelial ovarian cancer cells through the protein kinase C-mediated system. Cancer Lett. 166 (2001) 207-213
10. Daly M., and Obrams G.I. Epidemiology and risk assessment for ovarian cancer. Semin. Oncol. 25 (1998) 255-264
11. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur. J. Cancer Prev. 10 (2001) 125-129
12. Gnagy S., et al. Declining ovarian cancer rates in US women in relation to parity and oral contraceptive use. Epidemiology 11 (2000) 102-105
13. Minegishi T., et al. Functional expression of the recombinant human FSH receptor. J. Endocrinol. 141 (1994) 369-375
14. Zheng W.X., et al. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am. J. Pathol. 148 (1996) 47-53
15. Wang J., et al. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int. J. Cancer 103 (2003) 328-334
16. Choi J.H., et al. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 89 (2004) 5508-5516
17. Zheng W., et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol. Oncol. 76 (2000) 80-88
18. Parrott J.A., et al. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol. Cell. Endocrinol. 172 (2001) 213-222
19. Minegishi T., et al. A role of insulin-like growth factor I for follicle-stimulating hormone receptor expression in rat granulosa cells. Biol. Reprod. 62 (2000) 325-333
20. Grasso P., and Reichert L.E. Follicle-stimulating-hormone receptor-mediated uptake of Ca-45(2+) by cultured rat sertoli cells does not require activation of cholera toxin-sensitive or pertussis toxin-sensitive guanine-nucleotide binding-proteins or adenylate-cyclase. Endocrinology 127 (1990) 949-956
21. Richards J.S. Hormonal-control of gene-expression in the ovary. Endocrine Rev. 15 (1994) 725-751
22. Sairam M.R., et al. Follitropin signal transduction: alternative splicing of the FSH receptor gene produces a dominant negative form of receptor which inhibits hormone action. Biochem. Biophys. Res. Commun. 226 (1996) 717-722
23. Simoni M., Gromoll J., and Nieschlag E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocrine Rev. 18 (1997) 739-773
24. Dierich A., et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc. Natl. Acad. Sci. US Am. 95 (1998) 13612-13617
25. Bose C.K. Follicle stimulating hormone receptor (FSHR) antagonist and epithelial ovarian cancer (EOC). J. Exp. Ther. Oncol. 6 (2007) 201-204
26. Syed V., et al. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 61 (2001) 6768-6776
27. Mishra S., et al. Prohibitin: a potential target for new therapeutics. Trends Mol. Med. 11 (2005) 192-197
28. Shih Ie M., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164 (2004) 1511-1518
29. Kurman R.J., and Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 27 (2008) 151-160
30. Kindelberger D.W., et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31 (2007) 161-169
31. Crum C.P., et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr. Opin. Obstet. Gynecol. 19 (2007) 3-9
32. Shushan A., et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil. Steril. 65 (1996) 13-18
33. Luo M.P., et al. Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. Gynecol. Oncol. 67 (1997) 277-284
34. Ji Q., et al. Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int. J. Cancer 112 (2004) 803-814
35. Choi J.H., et al. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res. 66 (2006) 3912-3920
36. Cheung L.W., Leung P.C., and Wong A.S. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res. 66 (2006) 10902-10910
37. Lu J.J., et al. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol. Oncol. 79 (2000) 158-168
38. Choi J.H., et al. Gonadotropins and ovarian cancer. Endocr. Rev. 28 (2007) 440-461
39. Chu S., et al. FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol. Hum. Reprod. 8 (2002) 426-433
40. D'Andrilli G., Giordano A., and Bovicelli A. Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes. Open. Clin. Cancer J. 2 (2008) 7-12
41. Ratoosh S.L., et al. Hormonal regulation of the synthesis and mRNA content of the regulatory subunit of cyclic AMP-dependent protein kinase type II in cultured rat ovarian granulosa cells. J. Biol. Chem. 262 (1987) 7306-7313
42. Jahnsen T., et al. Molecular cloning, cDNA structure, and regulation of the regulatory subunit of type II cAMP-dependent protein kinase from rat ovarian granulosa cells. J. Biol. Chem. 261 (1986) 12352-12361
43. Tashiro H., et al. c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression. Int. J. Cancer 50 (1992) 828-833
44. Kohler M., et al. EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res. 9 (1989) 1537-1547
45. Bauknecht T., et al. J. Cancer Res. Clin. Oncol. 115 (1989) 193-199
46. Bauknecht T., et al. Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors (EGF-R) and EGF-like factors (EGF-F). Med. Oncol. Tumor Pharm. 6 (1989) 121-127
47. Fishman D.A., et al. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invas. Metast. 18 (1998) 15-26
48. Hagglund A.C., et al. Regulation and localization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse ovary during gonadotropin-induced ovulation. Endocrinology 140 (1999) 4351-4358
49. Ellerbroek S.M., et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 61 (2001) 1855-1861